MRC Epidemiology Unit

 

Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study.

Mokry LE, Zhou S, Guo C, Scott RA, Devey L, Langenberg C, Wareham NJ, Waterworth D, Cardon L, Sanseau P, Davey Smith G, and Richards JB

Scientific reports. Feb 2018

(DOI : 10.1038/s41598-019-45747-2)

---